That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

Pierre Beaurang Biography and Net Worth

Insider of Nurix Therapeutics

Pierre Beaurang is Chief Business Officer for Nurix Therapeutics, Inc.

He received a graduate degree and an undergraduate degree from Boston University and a doctorate from the University of California, Berkeley.

What is Pierre Beaurang's net worth?: The estimated net worth of Pierre Beaurang is at least $267,831.20 as of July 12th, 2021. Mr. Beaurang owns 11,830 shares of Nurix Therapeutics stock worth more than $267,831 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Beaurang may own. Learn More about Pierre Beaurang's net worth.
How do I contact Pierre Beaurang?: The corporate mailing address for Mr. Beaurang and other Nurix Therapeutics executives is , , . Nurix Therapeutics can also be reached via phone at 415-660-5320 and via email at [email protected]. Learn More on Pierre Beaurang's contact information.
Has Pierre Beaurang been buying or selling shares of Nurix Therapeutics?: Pierre Beaurang has not been actively trading shares of Nurix Therapeutics in the last ninety days. Most recently, Pierre Beaurang sold 7,500 shares of the business's stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $29.86, for a transaction totalling $223,950.00. Learn More on Pierre Beaurang's trading history.
Who are Nurix Therapeutics' active insiders?: Nurix Therapeutics' insider roster includes Pierre Beaurang (Insider), Gwenn Hansen (Insider), and Christine Ring (General Counsel). Learn More on Nurix Therapeutics' active insiders.
Are insiders buying or selling shares of Nurix Therapeutics?: In the last twelve months, insiders at the sold shares 23 times. They sold a total of 110,728 shares worth more than $2,215,543.67. The most recent insider tranaction occured on November, 1st when CFO Houte Hans Van sold 3,546 shares worth more than $86,096.88. Insiders at Nurix Therapeutics own 9.8% of the company. Learn More about insider trades at Nurix Therapeutics.
Information on this page was last updated on 11/1/2024.

Pierre Beaurang Insider Trading History at Nurix Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/10/2021	Sell	7,500	$29.86	$223,950.00
7/12/2021	Sell	7,500	$23.92	$179,400.00	11,830
6/10/2021	Sell	7,500	$29.37	$220,275.00	11,830
4/12/2021	Sell	7,500	$27.28	$204,600.00

Pierre Beaurang Buying and Selling Activity at Nurix Therapeutics

Nurix Therapeutics Company Overview

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Today's Range

Now: $22.37

$22.10

$23.09

50 Day Range

MA: $24.45

$21.54

$28.14

2 Week Range

Now: $22.37

$5.65

$29.56

Volume

729,004 shs

Average Volume

905,370 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Claim your FREE 2024 Gold Guide